Tag Archive for: Aristea Therapeutics

Due to safety concerns, Aristea Therapeutics announced Friday it is discontinuing the development of its Phase II lead program RIST4721. As a result, the San Diego-based biotech is also dissolving its business.

A review of the latest executive moves in the pharma industry over the past several months.